
We like to see pharma companies practicing what they preach. One example above all others is the excellent all-diabetes professional cycling team from Danish insulin giant Novo Nordisk (NOV: N). Proving that people with diabetes can lead full and active lives is what they do best – which also happens to be a great promotion for the company. The men’s cycling team, which kicks off its second season at the Tour de San Luis in Argentina on Monday, is at the forefront of Team Novo Nordisk, a global all-diabetes sports team of cyclists, triathletes and runners. The team aims to inspire, educate and empower people affected by diabetes by proving that there are no limits to what you can do.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze